Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.

Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruit, W. H., Goey, S. H., Calabresi, F., Lindemann, A., Stahel, R. A., Poliwoda, H., Osterwalder, B., Stoter, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033853/
https://www.ncbi.nlm.nih.gov/pubmed/7779731
_version_ 1782136928217333760
author Kruit, W. H.
Goey, S. H.
Calabresi, F.
Lindemann, A.
Stahel, R. A.
Poliwoda, H.
Osterwalder, B.
Stoter, G.
author_facet Kruit, W. H.
Goey, S. H.
Calabresi, F.
Lindemann, A.
Stahel, R. A.
Poliwoda, H.
Osterwalder, B.
Stoter, G.
author_sort Kruit, W. H.
collection PubMed
description Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%; CI 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-alpha appeared to be only moderately active.
format Text
id pubmed-2033853
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20338532009-09-10 Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Kruit, W. H. Goey, S. H. Calabresi, F. Lindemann, A. Stahel, R. A. Poliwoda, H. Osterwalder, B. Stoter, G. Br J Cancer Research Article Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%; CI 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-alpha appeared to be only moderately active. Nature Publishing Group 1995-06 /pmc/articles/PMC2033853/ /pubmed/7779731 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kruit, W. H.
Goey, S. H.
Calabresi, F.
Lindemann, A.
Stahel, R. A.
Poliwoda, H.
Osterwalder, B.
Stoter, G.
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
title Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
title_full Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
title_fullStr Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
title_full_unstemmed Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
title_short Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
title_sort final report of a phase ii study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033853/
https://www.ncbi.nlm.nih.gov/pubmed/7779731
work_keys_str_mv AT kruitwh finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT goeysh finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT calabresif finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT lindemanna finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT stahelra finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT poliwodah finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT osterwalderb finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma
AT stoterg finalreportofaphaseiistudyofinterleukin2andinterferonalphainpatientswithmetastaticmelanoma

Ejemplares similares